Position in DSGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$18,566,661
+$7,499,978 QoQ
Shares Held
1,744,987
+47.9% QoQ
Ownership
2.79%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 96%
Shared 0%
None 4%
Common Shares in DSGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Driehaus Capital Management LLC holds $3,010,622,183 across 56 Biotechnology names. DSGN ranks #35 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PRAX |
Praxis Precision Medicines, Inc.
|
949,225 | $305,830,802 | |
| 2 | XENE |
Xenon Pharmaceuticals Inc.
|
4,491,653 | $261,189,621 | |
| 3 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
6,395,922 | $232,299,887 | |
| 4 | APGE |
Apogee Therapeutics, Inc.
|
1,920,800 | $161,673,736 | |
| 5 | EWTX |
Edgewise Therapeutics, Inc.
|
4,477,942 | $141,055,173 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
2,790,785 | $140,767,195 | |
| 7 | DFTX |
Definium Therapeutics, Inc.
|
5,911,889 | $111,734,702 | |
| 8 | SEPN |
Septerna, Inc.
|
4,395,572 | $105,625,595 |
All Filings in DSGN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $18,566,661 | 1,744,987 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $11,066,683 | 1,179,817 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $8,104,057 | 1,076,236 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $3,626,915 | 1,076,236 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,525,720 | 913,399 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $4,788,425 | 776,082 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||